Literature DB >> 28302761

Performance Characteristics of the Whole-Body Discovery IQ PET/CT System.

Gabriel Reynés-Llompart1, Cristina Gámez-Cenzano2, Inmaculada Romero-Zayas2, Laura Rodríguez-Bel2, José L Vercher-Conejero2, Josep M Martí-Climent3.   

Abstract

The aim of this study was to assess the physical performance of a new PET/CT system, the Discovery IQ with 5-ring detector blocks.
Methods: Performance was measured using the National Electrical Manufacturers Association NU2-2012 methodology. Image quality was extended by accounting for different acquisition parameters (lesion-to-background ratios [8:1, 4:1, and 2:1] and acquisition times) and reconstruction algorithms (VUE-point HD [VPHD], VPHD with point-spread-function modeling [VPHD-S], and Q.Clear). Tomographic reconstruction was also assessed using a Jaszczak phantom. Additionally, 30 patient lesions were analyzed to account for differences in lesion volume and SUV quantification between reconstruction algorithms.
Results: Spatial resolution ranged from 4.2 mm at 1 cm to 8.5 mm at 20 cm. Sensitivity measured at the center and at 10 cm was 22.8 and 20.4 kps/kBq, respectively. The noise-equivalent counting rate peak was 124 kcps at 9.1 kBq/cm3 The scatter fraction was 36.2%. The accuracy of correction for count losses and randoms was 3.9%. In the image quality test, contrast recovery for VPHD, VPHD-S, and Q.Clear ranged from 18%, 18%, and 13%, respectively (hot contrast; 10-mm sphere diameter; ratio, 2:1), to 68%, 67%, and 81%, respectively (cold contrast; 37-mm sphere diameter; ratio, 8:1). Background variability ranged from 3.4%, 3.0%, and 2.1%, respectively (ratio, 2:1), to 5.5%, 4.8%, and 3.7%, respectively (ratio, 8:1). On Q.Clear reconstruction, the decrease in the penalty term (β) increased the contrast recovery coefficients and background variability. With the Jaszczak phantom, image quality increased overall when a reconstruction algorithm modeling the point-spread function was used, and use of Q.Clear increased the signal-to-noise ratio. Lesions analyzed using VPHD-S and Q.Clear had an SUVmean of 6.5 ± 3 and 7 ± 3, respectively (P < 0.01), and an SUVmax of 11 ± 4.8 and 12 ± 4, respectively (P < 0.01). No significant difference in mean lesion volume was found between algorithms.
Conclusion: Among the various Discovery bismuth germanium oxide-based PET/CT scanners, the IQ with 5-ring detector blocks has the highest overall performance, with improved sensitivity and counting rate performance. Q.Clear reconstruction improves the PET image quality, with higher recovery coefficients and lower background variability.
© 2017 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  Discovery IQ; NEMA NU 2-2012; PET/CT; Q.Clear

Mesh:

Year:  2017        PMID: 28302761     DOI: 10.2967/jnumed.116.185561

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  18 in total

1.  Performance evaluation of the 5-Ring GE Discovery MI PET/CT system using the national electrical manufacturers association NU 2-2012 Standard.

Authors:  Tinsu Pan; Samuel A Einstein; Srinivas Cheenu Kappadath; Kira S Grogg; Cristina Lois Gomez; Adam M Alessio; William C Hunter; Georges El Fakhri; Paul E Kinahan; Osama R Mawlawi
Journal:  Med Phys       Date:  2019-05-31       Impact factor: 4.071

2.  New standards for phantom image quality and SUV harmonization range for multicenter oncology PET studies.

Authors:  Go Akamatsu; Naoki Shimada; Keiichi Matsumoto; Hiromitsu Daisaki; Kazufumi Suzuki; Hiroshi Watabe; Keiichi Oda; Michio Senda; Takashi Terauchi; Ukihide Tateishi
Journal:  Ann Nucl Med       Date:  2022-01-14       Impact factor: 2.668

3.  Prospective F-18 FDOPA PET Imaging Study in Human PD.

Authors:  Vijay Dhawan; Martin H Niethammer; Martin L Lesser; Karalyn N Pappas; Matthew Hellman; Toni M Fitzpatrick; David Bjelke; Jaskirat Singh; Loreta M Quatarolo; Yoon Young Choi; Alice Oh; David Eidelberg; Thomas Chaly
Journal:  Nucl Med Mol Imaging       Date:  2022-04-12

Review 4.  Evidence-based management of incidental focal uptake of fluorodeoxyglucose on PET-CT.

Authors:  Deborah Pencharz; Malavika Nathan; Thomas L Wagner
Journal:  Br J Radiol       Date:  2018-01-31       Impact factor: 3.039

5.  NEMA Performance Evaluation of CareMiBrain dedicated brain PET and Comparison with the whole-body and dedicated brain PET systems.

Authors:  Laura Moliner; Maria J Rodríguez-Alvarez; Juan V Catret; Antonio González; Víctor Ilisie; José M Benlloch
Journal:  Sci Rep       Date:  2019-10-29       Impact factor: 4.379

6.  Impact of PET reconstruction protocols on quantification of lesions that fulfil the PERCIST lesion inclusion criteria.

Authors:  Joke Devriese; Laurence Beels; Alex Maes; Christophe Van de Wiele; Hans Pottel
Journal:  EJNMMI Phys       Date:  2018-12-07

7.  Image quality evaluation in a modern PET system: impact of new reconstructions methods and a radiomics approach.

Authors:  Gabriel Reynés-Llompart; Aida Sabaté-Llobera; Elena Llinares-Tello; Josep M Martí-Climent; Cristina Gámez-Cenzano
Journal:  Sci Rep       Date:  2019-07-23       Impact factor: 4.379

8.  Feasibility of diffusion-weighted imaging with DWIBS in staging Hodgkin lymphoma in pediatric patients: comparison with PET/CT.

Authors:  Dobromila Baranska; Katarzyna Matera; Michal Podgorski; Magdalena Gorska-Chrzastek; Karolina Krajewska; Joanna Trelinska; Piotr Grzelak
Journal:  MAGMA       Date:  2018-11-29       Impact factor: 2.310

9.  The impact of MR-based attenuation correction in spinal cord FDG-PET/MR imaging for neurological studies.

Authors:  Valentina Brancato; Pasquale Borrelli; Vincenzo Alfano; Marco Picardi; Mario Mascalchi; Emanuele Nicolai; Marco Salvatore; Marco Aiello
Journal:  Med Phys       Date:  2021-09-13       Impact factor: 4.506

10.  Measurement and Evaluation of Quantitative Performance of PET/CT Images before a Multicenter Clinical Trial.

Authors:  Yanjia Zhu; Caizheng Geng; Jia Huang; Juzhen Liu; Ning Wu; Jun Xin; Hao Xu; Lijuan Yu; Jianhua Geng
Journal:  Sci Rep       Date:  2018-06-13       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.